Some of the limitations of GTI2040 can be avoided in CALAA‐01 by encapsulating RRM2‐specific siRNA within nanoparticles, and its efficacy has been evaluated in phase I clinical trials in patients with melanoma;[42] however, sufficient evidence for the antitumor effects of CALAA‐01 is lacking. This evidence concerns the gene RRM2 and melanoma.